Want to see GB:CRTX full AI Analyst Report?
Amur Minerals (CRTX) AI Stock Analysis
Amur Minerals
(LSE:CRTX)
The score is driven primarily by weak financial performance (minimal/zero revenue, ongoing losses, and sustained cash burn), supported by bearish technical positioning (price below major moving averages and weak momentum). Valuation provides limited support due to the negative P/E and lack of dividend data.
Amur Minerals (CRTX) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 3.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 169.37K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 0.75
- Revenue Growth
- ―
- EPS Growth
- -6.87%
- Country
- UK
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Amur Minerals Business Overview & Revenue Model
Company Description
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor o...
How the Company Makes Money
Amur Minerals’ business model is typical of an exploration-stage mining company: it seeks to create value by acquiring, exploring, delineating, and advancing mineral projects toward development or monetization. For much of its history, the company ha...
Amur Minerals Financial Statement Overview
Summary
Overall fundamentals are weak: revenue is minimal and fell to 0 in 2025, losses remain deep with notable volatility (larger 2025 net loss), and operating/free cash flow are persistently negative with worsening cash burn. The main offset is a low-risk capital structure with zero debt, but equity has weakened and ROE is meaningfully negative.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 19.98K | 56.88K | 0 | 0 |
| Gross Profit | -13.46K | -117.00K | 16.78K | -3,792 | 0 | 0 |
| EBITDA | -2.73M | -2.09M | -449.07K | ― | -1.95M | -1.75M |
| Net Income | -2.39M | -1.90M | -485.05K | -247.74K | -2.45M | -1.54M |
Balance Sheet | ||||||
| Total Assets | 2.92M | 1.80M | 1.82M | 160.53K | 23.89M | 31.24M |
| Cash, Cash Equivalents and Short-Term Investments | 2.27M | 1.13M | 1.28M | 1,264 | 2.90M | 4.93M |
| Total Debt | 0 | 0 | 0 | 496.75K | 0 | 0 |
| Total Liabilities | 343.00K | 381.00K | 341.00K | 920.19K | 765.65K | 1.13M |
| Stockholders Equity | 2.58M | 1.42M | 1.48M | 4.12M | 23.13M | 30.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.58M | -1.97M | -961.00K | -2.77M | -2.99M | -2.26M |
| Operating Cash Flow | -2.58M | -1.97M | -933.00K | -2.77M | -3.35M | -1.83M |
| Investing Cash Flow | 35.00K | -31.00K | 2.33M | 34.93M | -511.00K | 6.04M |
| Financing Cash Flow | 4.47M | 1.84M | -67.00K | -31.45M | 968.00K | 0 |
Amur Minerals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRTX, the sentiment is Negative. The current price of 8.75 is below the 20-day moving average (MA) of 8.91, below the 50-day MA of 9.94, and below the 200-day MA of 11.12, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 20.77 is Positive, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRTX.
Amur Minerals Peers Comparison
Overall Rating
- GB:CRTX44Neutral
GB:CIZ38Underperform
GB:NFX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:CRTX | 44Neutral | GBP 6.97M | -1.76 | -119.45% | ― | ― | -6.87% |
| GB:CIZ | 38Underperform | GBP 5.28M | -6.88 | 192.61% | ― | ― | 42.86% |
| GB:NFX | 38Underperform | GBP 2.74M | -2.23 | -83.53% | ― | ― | 93.02% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:CRTX | Amur Minerals | 8.75 | -3.25 | -27.08% | |
| GB:NFX | Nuformix Plc | 0.10 | -0.38 | -78.35% | |
| GB:CIZ | Cizzle Biotechnology Holdings PLC | 1.10 | -0.60 | -35.29% |
Amur Minerals Corporate Events
CRISM Therapeutics Issues New Equity Ahead of ChemoSeed Trial Progress
PositiveCRISM Therapeutics Corporation has agreed to issue 472,222 new ordinary shares at 9 pence per share to a consultant, expanding its equity base as it advances its clinical-stage oncology drug delivery platform. The new shares are expected to be admitt...
CRISM Therapeutics Sets AGM Date as Phase 2 Glioblastoma Trial Recruitment Begins
PositiveCRISM Therapeutics Corporation has called its Annual General Meeting for 27 October 2026 in London, with the formal notice now posted to shareholders and available on the company’s website. The meeting underlines routine governance for the AIM-...
CRISM Therapeutics advances Phase 2 glioblastoma trial and strengthens funding for ChemoSeed platform
PositiveCRISM Therapeutics reported encouraging progress in the first half of 2026, highlighted by the opening of its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in resectable glioblastoma and the start of patient recruitment. The study...
CRISM Therapeutics names seasoned healthcare dealmaker as chair amid Phase 2 trial push
PositiveCRISM Therapeutics has appointed experienced healthcare executive Dr Charles Spicer as Non-Executive Chair, effective 1 October 2026, with Interim Executive Chairman Andrew Webb returning to his role as chief executive. Spicer’s 25-year track r...
CRISM Therapeutics Starts Phase II ChemoSeed Trial in Glioblastoma
PositiveCRISM Therapeutics has activated the first clinical site for its Phase II trial of irinotecan ChemoSeed in glioblastoma, marking a key step in moving its lead localised chemotherapy platform into active patient recruitment. The company’s immedi...
CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial
PositiveCRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial site in the UK, clearing a key operational step toward starting patient recruitment for its Phase II study in the coming weeks. The trial will test irinotecan C...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026